

LAW OFFICES OF  
**ALBERT WAI-KIT CHAN, PLLC**  
WORLD PLAZA, SUITE 604  
141-07 20TH AVENUE  
WHITESTONE, NEW YORK 11357

718-799-1000  
FAX 718-357-8552  
CHANK@KITCHANLAW.COM



**ALBERT WAI-KIT CHAN, PH.D., J.D.**  
Biographical Information

Dr. Albert Wai-Kit Chan is the Partner of the Law Offices of Albert Wai-Kit Chan, PLLC, practicing in all areas of intellectual property law (including patents, trademarks, copyrights, business transactions, litigation, licensing, technology transfer, evaluation, and trade secrets) and specializing in biotechnology. He works extensively with clients ranging from individual inventors to well-established prestigious research institutes in the U.S., China, and abroad. Dr. Chan is founder and director of the United States-China Intellectual Property Institute, Inc., a non-profit organization. Dr. Chan is a registered foreign lawyer in Hong Kong, where he also heads Albert Wai-Kit Chan Intellectual Property Limited.

陈伟杰博士是美国纽约陈伟杰律师事务所的合伙人，精通知识产权法领域各类法律实务（包括专利、商标、著作权、商业交易、诉讼、专利许可、技术转让、价值评估以及商业秘密），尤其擅长生物技术。陈博士的客户包括来自美国、中国和世界各地的发明人及著名的研究机构。中美知知识产权协会是一个非盈利性组织，陈博士作为创办人同时身兼会长一职。陈博士现为香港的注册外地律师，并于香港设立了陈伟杰知识产权有限公司。

陳偉傑博士是美國紐約陳偉傑律師事務所的管理合夥人，精通知識產權法領域各類法律實務（包括專利、商標、著作權、商業交易、訴訟、專利許可、技術轉讓、價值評估以及商業秘密），尤其擅長生物技術。陳博士的客戶包括來自美國、中國和世界各地的發明人及著名的研究機構。中美知知識產權協會是一個非盈利性組織，陳博士作為創辦人同時身兼會長一職。陳博士現為香港的註冊外地律師，並於香港設立了陳偉傑知識產權有限公司。



Jyh-An Lee is an Associate Professor of Law at the Chinese University of Hong Kong, where he serves as the Assistant Dean for Undergraduate Studies and as the Director of the LLB Programme. He holds a J.S.D. from Stanford Law School and an LL.M from Harvard Law School. Dr. Lee has published extensively in both English and Chinese on various aspects of intellectual property and Internet law. His research appears in leading academic journals, such as the *Wake Forrest Law Review*, *Virginia Journal of International Law*, *Columbia Journal of Law & the Arts*, *Oregon Law Review*, *Vanderbilt Journal of Entertainment and Technology Law*, *Jurimetrics*, *Minnesota Journal of Law, Science & Technology*, *Boston University Journal of Science & Technology Law*, *Cardozo Arts & Entertainment Law Review*, *Computer Law & Security Review*, *European Intellectual Property Review (EIPR)*, *Hastings Business Law Journal*, *Washington International Law Journal*, etc. His authored/edited books include *Nonprofit Organizations and the Intellectual Commons* (Edward Elgar, 2012), *Intellectual Property Law in China* (Wolters Kluwer, 2<sup>nd</sup> edn, 2021, co-authored with Peter Ganea, Danny Friedmann, and Douglas Clark), and *Artificial Intelligence and Intellectual Property* (Oxford University Press, 2021, co-edited with Reto M. Hilty and Chung-Chung Liu).

During his studies at Stanford Law School, Dr. Lee was appointed as the John M. Olin Fellow in Law and Economics. Prior to joining the Chinese University of Hong Kong, he taught at the National Chengchi University and was an Associate Research Fellow at the Center for Information Technology Innovation at Academia Sinica in Taiwan. He was the Legal Lead and Co-Lead of Creative Commons Taiwan (2011–2014) and an advisory committee member for Copyright Amendment at the Taiwan Intellectual Property Office (TIPO) at the Ministry of Economic Affairs (2011–2014). He has been the Legal Lead of the Creative Commons Hong Kong Chapter since October 2018. Professor Lee is currently a member of the European Center for E-Commerce & Internet Law advisory board, which is affiliated with the University of Vienna. In 2016, he was appointed as a domain name dispute resolution panelist by the Asian Domain Name Dispute Resolution Centre (ADNDRC) and continues to serve in this capacity. Dr. Lee is also the Vice President of the Asia Innovation and Intellectual Property Society. Professor Lee has been featured on ABC News, BBC News, Bloomberg News, Financial Times, Fortune, and South China Morning Post as an expert on intellectual property and Internet law. Before starting his academic career, he was a practicing lawyer in Taiwan, specializing in technology and business transactions.



**Mr. CHEUNG Wai Fung, Grover**

Founder of Qi Diagnostics Limited

Founder of Groken Bioscience Limited

BSc Biochemistry (Warwick, UK), MSc Business Management (Imperial, UK), MSc Biochemical and Biomedical Science (CUHK)

Mr. Grover Cheung is the founder of Qi Diagnostics Limited which is developing a revolutionizing non-invasive diagnostic technology of “A breath analyzer to diagnose multiple diseases”. He also founded Groken Bioscience Limited, an integrated genomic sequencing and bioinformatics services provider to universities, research institutes and pharmaceutical companies.

Mr. Grover Cheung obtained two master degrees in business management and biomedical science from Imperial College London and The Chinese University of Hong Kong. While he was the Regional Manager in BGI, he established the sales and marketing team for research sequencing service and clinical genomics service. He also leads the Bioinformatics Cloud Laboratory of BGI providing customised bioinformatics analysis to researchers and pharmaceutical companies in Asia. Under his leadership, the market share and sales revenue of BGI has increased significantly.

## Biography



**Prof. Lo Yuk Lam**

President, the Hong Kong Bio-Med Innotech Association

Qualified as a chemist, Professor Lo started his career as a Junior Scientist at the Cambridge Memorial Hospital in Ontario, Canada and advanced to become the Clinical Chemist. In 1979, he joined Bio-Rad Laboratories Canada (Bio-Rad), a company that specializes in reagents and instruments for use in laboratories and hospitals. His dynamic acumen and diligence soon accredited him to being appointed as National Sales & Marketing Director, in a course of five years. Later he became the President of Bio-Rad Asia Pacific and established the first office for Bio-Rad in Hong Kong. When Professor Lo was headhunted by PerkinElmer Life and Analytical Sciences and subsequently became the Asia-Pacific Chairman and President of PerkinElmer

Professor Lo is currently serving as the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau HKSAR, an Executive Committee Member of the Chinese Manufacturers' Association of Hong Kong (CMA) and Chairman of the Education Committee of CMA. Professor Lo is also the Honorary Founding Chairman of Hong Kong Bio-Organization. Professor Lo served as chairman of the HKSAR Committee on Biotechnology. He had been appointed a Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund, HKSAR.

## Biography



**Dr. Yu-Fen Chang**

Founder & CEO, LumiSTAR Biotechnology, Inc.

Dr. Chang worked on projects of development of a variety of luminescent and fluorescent protein-based indicators during her PhD, which can be used in cellular dynamics measurements and real-time tumor tracking. She was awarded the Japanese Society for Promotion of Science (JSPS) fellowship in 2011 to incorporate these indicators into optogenetic tools for studies of neurons and developing more advanced imaging technology/platform. Her research results were published in several high-impact journals. She has rich experience both in luminescent/fluorescent proteins and its application. Later, she was awarded a research grant from BHF (2013-2016) to support her research at John Radcliffe Hospital in Oxford University UK, where all of her developed technologies were integrated together for applications in drug screening and clinical research. She founded LumiSTAR Biotechnology with Dr. Min-Wen Chung in 2016 and was frequently invited to give talks in Japan and Taiwan for her research and viewpoints on future technology. After outbreak of COVID-19, she leads the company in developing diagnostics kits and high throughput drug screening/ vaccine validation platforms.

## Biography




**Dr. John Luk**

Founder & CEO, Arbele Corp

Dr. John Luk is educated and trained at the University of Hong Kong, Karolinska (Stockholm), and Harvard (Boston). Prior to establishing Arbele, he was an academic professor for 18 years in the US, Hong Kong and Singapore, and a visiting associate professor at Harvard. Through his professorship at leading institutes, he was able to establish strong scientific, clinical, and industrial networks globally. He has published around 200 papers including NEJM, Cell, Nature Medicine, and Nature Genetics. Dr. John identified and patented CDH17 at HKU (Global Licensed to Arbele). In 2011, he found his path to the drug industry at Roche and Janssen Pharmaceutical, to lead drug discovery and development programs in oncology, immunology, and hepatitis.

## Biography



**Prof. Sai Ming Ngai**

Principal Consultant, OM Sciences Co Ltd

Prof. Ngai obtained his PhD in Biochemistry from University of Alberta, Canada. His laboratory first identified GmPHD5 can act as an important regulator for crosstalk between histone H3K4 di-methylation and H3K14 acetylation in response to salinity stress in soybean and demonstrated the mass spectrometry analysis of the variants of histone H3 and H4 and their posttranslational modifications (PTMs) in soybean varieties that published in BMC Plant Biol (2011 and 2009). His team is capable of handling proteomics, peptidomics and metabolomics and biosensor related researches on clinical samples (serum), herbs, jellyfish and soybean samples (salt-tolerant and salt-sensitive). Recently, he has successfully established high-throughput Top-down proteomics platform on PTMs studies for intact histone proteins.

## Biography



**Mr. Aldrin Or**

Founder & CEO, Curie Limited

Mr. Or came up with the idea behind Curie while developing nano scaffolding for human tissue engineering. The promising results in the lab have convinced him and other founders to pivot and focus on tackling COVID in 2020.

Curie developed C-Polar bioelectret to arrest, inactivate and eliminate high ratios of microbiome, including coronavirus, influenza and coxsackievirus, from fast air flow, with short contact time only. C-Polar's mechanism is independent from external energy, chemical consumption, and toxicity.

Mr. Or holds a BEng in Industrial Engineering from the Hong Kong University of Science and Technology (HKUST), and he has worked in the manufacturing and technology field for 10 years.



## Biography



**Dr. Daniel So**

CEO & Co-Founder, Genvida (HK) Co. Ltd

Dr. Daniel So received his Ph.D. in electrical engineering from the University of Wisconsin-Madison and has 25+ years of R&D and management experience in Silicon Valley. He is currently the co-founder and CEO of Genvida, a nanobiotech startup in the Hong Kong Science Park. Previously, he worked for Intel, HP / Agilent and Motorola, and consulted for Life Technologies / ThermoFisher. He was the co-founder and CTO of Scenterra.

His expertise centers on micro-/nanoscale technology. Notable scientific accomplishments include: (1) world's first implementation of chromeless phase-shift mask technique for the fabrication of T-gate in millimeter-wave integrated circuits, (2) realtime programmable LiPMAS (nanoLight-Pipe MicroArray Synthesis) system for maskless fabrication of microarrays, and (3) portable SONAS (SOLID-state NANopore Sequencing) technology for low cost, realtime sequencing.



### **Nelson Tong's Biography**

Nelson S. Tong is a venture financing consultant / business advisor. Nelson has 5+ years of experience in pro forma financial statement, early-stage venture valuation, and business plan development. He has been involved in several venture financing and medical device licensing transactions, managing clients from first contact to closing. Nelson was a founding team member of 2 B2B startups offering solutions in managing innovation portfolio for early-stage ventures and tracking drug prescriptions for pharmaceutical marketing. He is a founding director of International Intangible Assets Institute – a non-profit organization dedicated to promoting innovation and fostering entrepreneurial ecosystem in order to support creation and growth of new ventures

Before 2016, Nelson spent 8+ years in biotechnology industry. He was the head of bioinformatics at a NIGMS-funded consortium providing biotechnology and pharmaceutical firms with critical structural genomics services (e.g., protein production, target selection, and protein structure determination). Nelson has worked with the Protein Data Bank to improve data management of three-dimensional structural data of protein targets important to new drug discovery. While working as a team member of a NIEHS-funded consulting group, Nelson contributed to building data science / machine learning pipeline and physiologically based pharmacokinetic model for assessing human exposure to environmental toxins.

Nelson received his M.B.A. from Rutgers Business School with triple concentrations in Finance, Entrepreneurship, and Business Strategy. He was awarded with 2 M.S. in Biostatistics and Systems Engineering from Rutgers Graduate School, and he authored a digital health research thesis on applying systems science to analyze deep brain stimulation and brain-wave biomarkers of Parkinson's disease. As a New Jersey Outstanding Scholar, Nelson earned his B.S. in Biological Sciences and Chemical Engineering from Rutgers School of Engineering. Nelson is currently pursuing the CFA charter with CFA Level II exam passed.

## Biography



### **Winfred Fan**

Winfred is a senior executive and entrepreneur with over 20 years of experience as CEO, CFO and advisor of businesses in technology, manufacturing, real estate and retail in the ANZ and Asia-Pacific region. Prior to moving back to Hong Kong in 2015, Winfred spent the first two decades of his career in Melbourne, firstly at a leading accounting and advisory firm in Australia where he acted as a key change agent working closely with clients in different industries helping them to restructure and grow. He then held senior positions at companies in various industries including retail, manufacturing, real estate, and telecommunication.

Winfred has been the CFO then CEO of Anywhere Networks, a global wireless and networking technology company headquartered in Hong Kong since 2015.

Winfred is a Chartered Accountant with a Bachelor of Commerce from Monash University, Melbourne. He is a member of the Chartered Accountants Australia and CPA Australia.

## Biography



**Dr. Gen Li**

**President & Founder, Phesi**

Dr. Gen Li is a pharmaceutical industry leader with a passion to improve patients' lives. Prior to founding Phesi in 2007, Dr. Li was Head of Productivity for Pfizer Worldwide Clinical Development, a position he assumed following Pfizer's acquisition of Pharmacia, where Dr. Li delivered the first implementation of productivity measurement for clinical development. While at Pharmacia and Pfizer, Dr. Li significantly contributed to the Centre for Medicines Research (CMR) International database for pharmaceutical R&D performance, assuring the collection of key clinical trial parameters as representative of the critical path for delivery. He was also instrumental in creating the KMR productivity mode. Previously, Dr. Li led the creation of the first computer-automated resource management system at Bristol-Myers Squibb. Dr. Li received the prestigious Upjohn Award from Pfizer/Pharmacia. He earned his Ph.D. in Biochemistry from Beijing University, and an MBA from the Johnson Graduate School of Management at Cornell University.

## Biography



**Mr. Jonathan Peachey**

Chief Operations Officer, Phesi

Jonathan Peachey is an industry expert who has led business and IT transformation across pharmaceutical R&D for 25 years. Jonathan came to Phesi after serving as a Board Director at Kinapse, where he transformed the advisory and outsourcing delivery model for life sciences companies. Previously, Jonathan delivered business transformation for IBM's EU pharmaceutical R&D consulting practice. Jonathan worked as a clinical Program Leader at GSK, Pfizer and Bristol-Myers Squibb. Jonathan's demonstrated capabilities span strategy, business and IT management, performance improvement and solution design, through to implementation. Jonathan holds a first class honours degree and an Advanced Strategy diploma from Saïd Business School, Oxford University.



**Rong Xie, M.Sc., LL.M., Patent Attorney**, has extensive experience in intellectual property law practice. His practice involves patent and trademark prosecution, patent interference, technology transfer, IP-related business transactions and cross-the-border investments. Over the years, he has advised clients in various industries including automotive electronics system, building material, construction, chemistry, fashion and software. He also assists in teaching IP classes at CUNY law school by preparing course materials and giving lectures. Mr. Xie has a bachelor's degree of law from Shanghai University of International Business and Economics (formerly known as "Shanghai Institute of Foreign Trade") (Shanghai, China), a master's degree of law from Washington University in St. Louis (Missouri, U.S.), and a master degree of science in computer science from Pace University (New York, U.S.). He is licensed to practice before the United States Patent and Trademark Office, the State of New York, and the United States Court of Appeals for the Federal Circuit.

谢融律师（科学硕士、法学硕士、专利律师）在知识产权法律实践方面拥有丰富经验。他的业务涉及专利和商标申请、专利干涉、技术转让、知识产权相关业务交易和跨境投资。多年来，他为各行各业的客户提供咨询服务，包括汽车电子系统、建筑材料、建筑、化学、时装和软件。他还通过准备课程材料和授课来协助在纽约市立大学法学院教授知识产权课程。谢律师拥有上海对外经济贸易大学（前身为“上海对外贸易学院”）的法学学士学位，美国密苏里州圣路易斯华盛顿大学的法学硕士学位，以及美国纽约佩斯大学的计算机科学硕士学位。他获准在美国专利商标局、纽约州和美国联邦巡回上诉法院执业。

**Dominic Lui (吕冠贤)**

**Education Background**

- MEng in Chemical Engineering, Imperial College London

**Working Experience**

- Patentability analysis
- Trademark, patent search, application business
- Technical translation

Mr. Lui received a combined bachelor's and master's degree in chemical engineering from Imperial College London, United Kingdom. After returning to Hong Kong, he first began his career in the semiconductor industry, responsible for the research and development of semiconductor assembly equipment, and subsequently entered the intellectual property industry. He has experience in patent search, application, analysis and protection. He is familiar with patent application and examination systems in many countries and regions, and is able to provide customers with a complete set of intellectual property protection strategies.

## Biography



**Keith Chan, Ph.D.**

Dr. Keith Chan is a pharmaceutical scientist, a regulator, a professor, and an entrepreneur. He obtained his Ph.D. degree in Pharmaceutics from the University of Minnesota. He is currently Senior Advisor of Cornerstone IP Foundation and Adjunct Professor at the Graduate Institute of Intellectual Property and Technology Management, College of Commerce, National Chengchi University at Taiwan. He is also a Senior Partner at the Bright Spot Management Consultants Corp based on China, Hong Kong, and Taiwan. He is Senior Research Fellow at the Institute of International Intellectual Property at Beijing University Law School. He also serves as Director of International Affairs, GloboAsia LLC, Rockville, MD, USA and as advisors for several research institutes and regulatory agencies in Asia, as well as consultants for various pharmaceutical firms in Asia and in the US.

Dr. Chan worked for Ciba-Geigy Corporation (now Novartis) in Ardsley, New York for 15 years and held various senior and management positions. He published >150 abstracts/research articles in peer-reviewed journals and >200 professional presentations. He was elected fellow of the American Association of Pharmaceutical Scientists (AAPS) in 1995 for his scientific accomplishments on drug absorption in humans. He also worked for the US FDA as Division Director at the Office of Generic Drugs. In 1997, he co-founded GloboMax LLC, a drug development organization, in Hanover, Maryland in 1997 and served as a consultant for numerous multi-national pharmaceutical and biotech firms in the US, Europe, and Asia. GloboMax was acquired by ICON, plc in 2003 and Dr. Chan exited from the operation. He served as Professor and Adjunct Professor at the School of Pharmacy, University of Maryland at Baltimore for many years and also served as Adjunct Professor and National Board of Advisor, College of Pharmacy, the University of Minnesota since 1984. He also taught in Asia including National Defense Medical Center, National Yang Ming University in Taiwan and Shang Yang Pharmaceutical University in China.

Over the last 15 years, he assisted various Asian companies, organized numerous workshops and conferences in China, Taiwan, Hong Kong, Singapore, and Korea. He lectured frequently in Asia in the hope of upgrading their pharmaceutical industry. He had success in assisting several Asian companies in their technology transfers and licensing. He also managed those new drug development projects starting from IND up to NDA. Some of those drug candidates have now marketed and launched in Japan, the United States, Asia, and Europe. His new adventure is joining a professional strategy consulting firm to provide various financial and investment networks to those technology companies to strengthen their financial structure that leads to products development or market expansion.